Uganda - engleză - National Drug Authority

ciron drugs & pharmaceuticals pvt ltd - chlorpromazine - parenteral ordinary ampoules - 25mg/ml

Malta - engleză - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - chlorpromazine hydrochloride - film-coated tablet - chlorpromazine hydrochloride 25 mg - psycholeptics

Malta - engleză - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - chlorpromazine hydrochloride - film-coated tablet - chlorpromazine hydrochloride 100 mg - psycholeptics

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

may & baker limited - chlorpromazine hydrochloride - solution for injection - 25 mg/ml

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) - injection (depot) - 25 mg/ml - active: fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) excipient: benzyl alcohol nitrogen sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

clinect nz pty limited - levomepromazine hydrochloride 25 mg/ml equivalent to 22.5 mg/ml levomepromazine base;   - solution for injection - 25 mg/ml - active: levomepromazine hydrochloride 25 mg/ml equivalent to 22.5 mg/ml levomepromazine base   excipient: ascorbic acid sodium chloride sodium sulfite water for injection - nozinan is indicated in the management of terminal pain and accompanying restlessness or distress.

Noua Zeelandă - engleză - Medsafe (Medicines Safety Authority)

max health limited - levomepromazine hydrochloride 25 mg/ml - solution for injection - 25 mg/ml - active: levomepromazine hydrochloride 25 mg/ml excipient: ascorbic acid sodium chloride sodium sulfite water for injection - indicated in the management of terminal pain and accompanying restlessness or distress.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

tya pharmaceuticals - chlorpromazine hydrochloride (unii: 9wp59609j6) (chlorpromazine - unii:u42b7vya4p) - chlorpromazine hydrochloride 25 mg in 1 ml - for the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.).

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

state of florida doh central pharmacy - chlorpromazine hydrochloride (unii: 9wp59609j6) (chlorpromazine - unii:u42b7vya4p) - chlorpromazine hydrochloride 25 mg - for the management of manifestations of psychotic disorders. for the treatment of schizophrenia. to control nausea and vomiting. for relief of restlessness and apprehension before surgery. for acute intermittent porphyria. as an adjunct in the treatment of tetanus. to control the manifestations of the manic type of manic-depressive illness. for relief of intractable hiccups. for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervo

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

contract pharmacy services-pa - chlorpromazine hydrochloride (unii: 9wp59609j6) (chlorpromazine - unii:u42b7vya4p) - chlorpromazine hydrochloride 50 mg - for the management of manifestations of psychotic disorders. for the treatment of schizophrenia. to control nausea and vomiting. for relief of restlessness and apprehension before surgery. for acute intermittent porphyria. as an adjunct in the treatment of tetanus. to control the manifestations of the manic type of manic-depressive illness. for relief of intractable hiccups. for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. do not use in patients with known hypersensitivity to phenothiazines. do not use in comatose states or in the presence of large amounts of central nervo